share_log

6-K: Novo Nordisk A/S – Total Number of Voting Rights and Share Capital in Novo Nordisk A/S as of 26 April 2024

6-K: Novo Nordisk A/S – Total Number of Voting Rights and Share Capital in Novo Nordisk A/S as of 26 April 2024

諾和諾德 | 6-K：諾和諾德 -截至2024年4月26日的諾和諾德公司投票權和股本總數
美股sec公告 ·  04/26 20:43
牛牛AI助理已提取核心訊息
On April 26, 2024, Novo Nordisk A/S, a leading global healthcare company, announced an update to its share capital and voting rights structure as required by Section 32 of the Danish Capital Markets Act. The update followed changes that occurred within the month, as referenced in Company Announcement no 32/2024 dated April 24, 2024. The total number of shares now stands at 4,465,000,000, with a share capital of DKK 446,500,000. The A shares, each carrying 100 votes, total 1,074,872,000, while the B shares, with 10 votes each, total 3,390,128,000. This results in a total of 141,388,480,000 voting rights. Treasury shares are accounted for but do not carry voting rights at general meetings. Novo Nordisk, founded in 1923 and headquartered in Denmark, focuses on defeating serious chronic diseases and is present in 80 countries, marketing its products in approximately 170 countries. The company's B shares are traded on Nasdaq Copenhagen, and its ADRs are listed on the New York Stock Exchange under the ticker NVO.
On April 26, 2024, Novo Nordisk A/S, a leading global healthcare company, announced an update to its share capital and voting rights structure as required by Section 32 of the Danish Capital Markets Act. The update followed changes that occurred within the month, as referenced in Company Announcement no 32/2024 dated April 24, 2024. The total number of shares now stands at 4,465,000,000, with a share capital of DKK 446,500,000. The A shares, each carrying 100 votes, total 1,074,872,000, while the B shares, with 10 votes each, total 3,390,128,000. This results in a total of 141,388,480,000 voting rights. Treasury shares are accounted for but do not carry voting rights at general meetings. Novo Nordisk, founded in 1923 and headquartered in Denmark, focuses on defeating serious chronic diseases and is present in 80 countries, marketing its products in approximately 170 countries. The company's B shares are traded on Nasdaq Copenhagen, and its ADRs are listed on the New York Stock Exchange under the ticker NVO.
2024年4月26日，全球領先的醫療保健公司諾和諾德A/S宣佈按照《丹麥資本市場法》第32條的要求更新其股本和投票權結構。該更新是在本月內發生的變化之後進行的，如2024年4月24日第32/2024號公司公告所述。目前股票總數爲44.65億股，股本爲44.65億丹麥克朗。每股擁有100張選票的A股總票數爲1,074,872,000張，而B股每股有10張選票，總票數爲3,390,128,000張。這導致總共有141,388,48萬張投票權。庫存股已入賬，但在股東大會上不具有投票權。諾和諾德成立於1923年，總部位於丹麥，專注於戰勝嚴重的慢性病，業務遍及80個國家，產品銷往約170個國家。該公司的B股在哥本哈根納斯達克上市，其ADR在紐約證券交易所上市，股票代碼爲NVO。
2024年4月26日，全球領先的醫療保健公司諾和諾德A/S宣佈按照《丹麥資本市場法》第32條的要求更新其股本和投票權結構。該更新是在本月內發生的變化之後進行的，如2024年4月24日第32/2024號公司公告所述。目前股票總數爲44.65億股，股本爲44.65億丹麥克朗。每股擁有100張選票的A股總票數爲1,074,872,000張，而B股每股有10張選票，總票數爲3,390,128,000張。這導致總共有141,388,48萬張投票權。庫存股已入賬，但在股東大會上不具有投票權。諾和諾德成立於1923年，總部位於丹麥，專注於戰勝嚴重的慢性病，業務遍及80個國家，產品銷往約170個國家。該公司的B股在哥本哈根納斯達克上市，其ADR在紐約證券交易所上市，股票代碼爲NVO。
有用
沒用

該公告為獨立文件：

獨立文件1  查看翻譯

譯文內容由第三人軟體翻譯。


牛牛AI助手部分由第三方人工智慧模型基於資訊內容自動產生，只对除中国内地以外的地区提供。


以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。